Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)

CompletedOBSERVATIONAL
Enrollment

282

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

November 15, 2018

Study Completion Date

January 30, 2019

Conditions
Multiple Myeloma
Interventions
OTHER

No Intervention

As it was an observational study, no intervention was administered in this study.

Trial Locations (30)

1009

Hospital de Txagorritxu, Vitoria-Gasteiz

7120

H Son Espases, Palma

7198

Hospital Son Llatzer, Palma

8036

Hospital Clinico de Barcelona, Barcelona

8908

ICO Bellvitge, L'Hospitalet de Llobregat

9006

Hospital de Burgos, Burgos

11009

H Universitario Puerta del Mar, Cadiz

11408

H Jerez, Jerez de la Frontera

15706

H Clinico Universitario de Santiago, Santiago de Compostela

17007

Hospital Doctor Trueta ICO Girona, Girona

18014

H Virgen de las Nieves, Granada

19002

H U de Guadalajara, Guadalajara

20014

H de Donosti, Donostia / San Sebastian

21005

Hospital Juan Ramon Jimenez, Huelva

24001

Hospital de Leon, León

27003

Hospital Lucus Agusti, Lugo

28031

H Infanta Leonor, Madrid

28041

H 12 de Octubre, Madrid

29603

Hospital Costa del Sol, Marbella

31008

Complejo Hospitalario de Navarra, Pamplona

33394

H Universitario de Cabuenes, Gijón

37007

Hospital de Salamanca, Salamanca

38320

H U Canarias, San Cristóbal de La Laguna

39008

H Marques de Valdecilla, Santander

40002

Complejo Asistencial de Segovia, Segovia

41014

H. Nuestra Senora de Valme, Seville

43005

H Universitari de Tarragona Joan XXIII, Tarragona

45071

Complejo Hospitalario Toledo, Toledo

46010

H Clinico de Valencia, Valencia

50009

Hospital Clinico Universitario Lozano Blesa, Zaragoza

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03188536 - Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) | Biotech Hunter | Biotech Hunter